| Open Document File Size: 4,33 MBShare Result on Facebook
Company AEs / Nestle / Novartis Pharmaceuticals Corporation for the Dermatologic / / Event FDA Phase / / IndustryTerm treatment of psoriasis / psoriasis therapy / / MedicalCondition unmet medical need Psoriasis / autoimmune disorders / squamous cell carcinoma / basal cell carcinoma / severe psoriasis / Disease / treated latent tuberculosis / cutaneous candidiasis / chronic use / chronic / candidiasis / stroke / plaque psoriasis / cardiovascular disease / malignant melanoma / III psoriasis / oral candidiasis / respiratory tract infections / severe plaque psoriasis / complex disorder / myocardial infarction / melanocytic nevus / Secukinumab (AIN457) Psoriasis / cardiac disorders / psoriasis / normal inflammatory and immune responses / hypersensitivity / infection / hepatitis / common human skin diseases / inflammation / severe disease / infections / tuberculosis / chronic mucocutaneous candidiasis / systemic psoriasis / / MedicalTreatment phototherapy / / Organization Ophthalmic Drugs Advisory Committee / FDA / Advisory Committee / American Academy of Dermatology / / Position Investigator Global Assessment / Executive / physician / Major / / Product A2304 / A2211 / FDA / secukinumab / / Technology artificial intelligence / antibodies / /
SocialTag |
Secukinumab (AIN457) ADVISORY COMMITTEE BRIEFING MATERIAL: AVAILABLE FOR PUBLIC RELEASE Prepared by Novartis Pharmaceuticals Corporation for the